PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On May5, 2017, Pulmatrix, Inc. (the Company) issued a press
release announcing its financial results for the first fiscal
quarter ended March31, 2017. A copy of the press release is
furnished as Exhibit 99.1 hereto and is incorporated herein by
reference.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including
Exhibit99.1, is being furnished to Item 2.02 and shall not be
deemed filed for the purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Exchange
Act or the Securities Act of 1933, as amended, except as shall be
expressly set forth by reference in such a filing.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
| 99.1 |
Press Release, issued on May5, 2017 (furnished herewith to Item 2.02). |
About PULMATRIX, INC. (NASDAQ:PULM)
Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease. PULMATRIX, INC. (NASDAQ:PULM) Recent Trading Information
PULMATRIX, INC. (NASDAQ:PULM) closed its last trading session 00.00 at 2.91 with 185,172 shares trading hands.
